<code id='31F949BC3C'></code><style id='31F949BC3C'></style>
    • <acronym id='31F949BC3C'></acronym>
      <center id='31F949BC3C'><center id='31F949BC3C'><tfoot id='31F949BC3C'></tfoot></center><abbr id='31F949BC3C'><dir id='31F949BC3C'><tfoot id='31F949BC3C'></tfoot><noframes id='31F949BC3C'>

    • <optgroup id='31F949BC3C'><strike id='31F949BC3C'><sup id='31F949BC3C'></sup></strike><code id='31F949BC3C'></code></optgroup>
        1. <b id='31F949BC3C'><label id='31F949BC3C'><select id='31F949BC3C'><dt id='31F949BC3C'><span id='31F949BC3C'></span></dt></select></label></b><u id='31F949BC3C'></u>
          <i id='31F949BC3C'><strike id='31F949BC3C'><tt id='31F949BC3C'><pre id='31F949BC3C'></pre></tt></strike></i>

          
          WSS
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images

          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

          advertisement

          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion